A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of A-337 in Patients with Advanced Solid Tumors
Latest Information Update: 27 Apr 2021
Price :
$35 *
At a glance
- Drugs A 337 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 19 Mar 2020 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 16 Aug 2017 New trial record